Potentiation of anticancer agents
The present invention relates to carriers, conjugate and pharmaceutical compositions and their use to increase the potency of drugs and to modify the pharmacokinetics of compounds. More particularly, the present invention relates to conjugates comprising the carrier described herein and their use in the treatment and diagnostic of cancer.
1. A pharmaceutical composition comprising:
(a) a conjugate, or a pharmaceutically acceptable salt thereof, comprising:
(i) a polypeptide comprising the amino acid sequence of Angiopep-2 (SEQ ID NO:97); and
(ii) one to three paclitaxel molecules conjugated to said polypeptide, wherein each of said paclitaxel molecules is conjugated to said Angiopep-2 as shown below:
wherein the NH group is either the amino terminal amine or an amino group on a lysine at position 10 or position 15 of Angiopep-2; and
(b) macrogol 15 hydroxystearate (Solutol® HS 15).
2. The composition of claim 1 , wherein said polypeptide consists of the amino acid sequence of AngioPep-2 (SEQ ID NO:97).
3. The composition of claim 1 , wherein said polypeptide is about 19 amino acid to about 50 amino acids in length.
4. The composition of claim 1 further comprising mannitol or a buffer.
5. The composition of claim 1 further comprising a pharmaceutically acceptable carrier.
6. A composition comprising:
(a) a conjugate, or a pharmaceutically acceptable salt thereof, comprising:
(i) a polypeptide comprising the amino acid sequence of Angiopep-2 (SEQ ID NO:97); and
(ii) one to three paclitaxel molecules conjugated to said polypeptide, wherein said paclitaxel molecule(s) is conjugated to said Angiopep-2 as shown below:
wherein the NH group is either the amino terminal amine or an amino group on a lysine at position 10 or position 15 of Angiopep-2; and
(b) macrogol 15 hydroxystearate (Solutol® HS 15).
7. The conjugate of claim 6 , wherein said polypeptide consists of the amino acid sequence of Angiopep-2 (SEQ ID NO:97).
8. The composition of claim 6 , wherein said polypeptide is about 19 amino acid to about 50 amino acids in length.
9. The composition of claim 6 further comprising mannitol or a buffer.
10. The composition of claim 6 further comprising a pharmaceutically acceptable carrier.
11. The composition of claim 1 , wherein
three paclitaxel molecules are conjugated to said polypeptide.